SCHEMBL3376954

SCHEMBL3376954

CS(=O)(=O)Nc1ccc(-c2ccc(Cl)c(F)c2)c(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 3/20 0.48
GAA P10253 1/20 0.48
HPGD P15428 1/20 0.48
MAPK1 P28482 1/20 0.48
CYP17A1 P05093 2/20 0.47
PTGS2 P35354 2/20 0.44
HAVCR2 Q8TDQ0 2/20 0.43
SCN9A Q15858 1/20 0.42
PGR P06401 2/20 0.42
NR3C1 P04150 1/20 0.42
NR3C2 P08235 1/20 0.42
AR P10275 1/20 0.42
KIT P10721 2/20 0.41
ADRA2C P18825 1/20 0.41
ADRA1A P35348 1/20 0.41
ADRA1B P35368 1/20 0.41
KCNH2 Q12809 2/20 0.41
GRIN1 Q05586 1/20 0.41
GRIN2B Q13224 1/20 0.41
PTGS1 P23219 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3377400 0.91 KIF11 (0.48) KIF11GAAHPGDMAPK1CYP17A1
SCHEMBL3374747 0.91 KIF11 (0.51) KIF11GAAHPGDMAPK1CYP17A1
SCHEMBL3377083 0.89 PTGS2 (0.52) KIF11GAAHPGDMAPK1CYP17A1
SCHEMBL3379785 0.87 GAA (0.49) KIF11GAAHPGDMAPK1CYP17A1
SCHEMBL3378453 0.86 PGR (0.44) KIF11HPGDPTGS2PGRNR3C1
SCHEMBL3375785 0.85 KIF11 (0.59) KIF11CYP17A1SCN9ANR3C1AR
SCHEMBL3376946 0.85 CYP17A1 (0.51) KIF11CYP17A1PTGS2SCN9ANR3C1
SCHEMBL3378764 0.85 PTGS2 (0.51) KIF11GAAHPGDMAPK1CYP17A1
SCHEMBL3377016 0.85 KIF11 (0.64) KIF11HPGDPTGS2SCN9AKCNH2
SCHEMBL3932771 0.85 KIF11 (0.50) KIF11GAAHPGDMAPK1CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US claimed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO claimed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US claimed
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US disclosed
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US disclosed
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US disclosed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO disclosed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, HCN4, KCNH2 KIF11 3561/4885GAA 1564/4885HPGD 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.